Genentech, an affiliate of the Roche Group (RHHBY), has presented promising new results from its bispecific antibody program targeting CD20xCD3 T-cells at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition. The data highlighted the advantages of fixed-duration treatments with Columvi (glofitamab-gxbm) and Lunsumio (mosunetuzumab-axgb) for various aggressive and indolent lymphomas.
The company's long-term studies demonstrated that fixed-duration therapies with Columvi and Lunsumio result in sustained remissions post-treatment. Additionally, real-world data indicated a reduced travel burden for patients due to the infrequency of dosing schedules.
A pioneering presentation on the subcutaneous administration of Lunsumio revealed its non-inferiority compared to intravenous methods, maintaining a consistent safety profile. This could offer patients a more convenient outpatient experience with quicker administration times.
In the pivotal Phase II NP30179 trial, focused on individuals with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), three-year follow-up data showed that 40% of patients achieved a complete response (CR), with a median CR duration of 29.8 months. Most patients who reached complete remission by the end of their treatment remained in remission two years afterward. The safety profile remained consistent with prior analyses.
Further, four-year follow-up data from the critical Phase II GO29781 study of Lunsumio in patients with R/R follicular lymphoma (FL) revealed enduring remissions. Nearly two-thirds of patients achieving CR were alive and free from disease progression at 45 months. The study reported an overall response rate (ORR) of 77.8% and a CR rate of 60.0%. This study included patients with a history of disease progression within 24 months following frontline treatment (POD24), often considered challenging to treat. No new safety concerns emerged since the previous assessment.
Both clinical studies also documented the restoration of B-cell levels beginning 12-18 months after Columvi treatment and approximately 19 months following Lunsumio treatment. This is indicative of immune system recovery, reinforcing the efficacy of fixed-duration therapy. The recovery of B-cells is crucial for maintaining patients' immune system function after lymphoma treatment, as highlighted by the company.
